Aberrant Expression of EZH2 in Pediatric Patients with Myelodysplastic Syndrome: A Potential Biomarker of Leukemic Evolution

Figure 2

EZH2 expression by qRT-PCR in pediatric patients with MDS. (a) EZH2 expression from samples of healthy pediatric donors and pediatric patients with MDS. (b) Healthy pediatric donors and MDS subtypes. (c) Normal karyotypes versus abnormal karyotypes.

(a)

(b)

(c)